The Sd a blood group carbohydrate structure is expressed in the normal gastrointestinal mucosa. We reported previously that the expression of Sd a carbohydrate structures and B1,4-
Introduction of Sd a Carbohydrate Antigen in Gastrointestinal Cancer Cells Eliminates Selectin Ligands and Inhibits Metastasis
Yuki I. Kawamura, 1, 3 Rei Kawashima, 1 Ryuko Fukunaga, 1 Kazunari Hirai, 1 Noriko Toyama-Sorimachi, 1 Makoto Tokuhara, 2 Toshio Shimizu, 2 and Taeko Dohi   1   1 Department of Gastroenterology, Research Institute and 2 Department of Surgery, International Medical Center of Japan; and 3 GS platZ Co., Ltd., Tokyo, Japan
Abstract
The Sd a blood group carbohydrate structure is expressed in the normal gastrointestinal mucosa. We reported previously that the expression of Sd a carbohydrate structures and B1,4-N-acetylgalactosaminyltransferase (B1,4GalNAcT) activity responsible for Sd a synthesis were remarkably decreased in cancer lesions of the gastrointestinal tract. In this study, we found that Sd a antigen was expressed mainly in chief cells of normal stomach but not in cancer tissue by immunohistologic staining. In separated gastric mucosal cells, the Sd a glycolipids and B1,4GalNAcT activity were concentrated in a fraction that contained chief cells as a major population. We cloned the cDNA encoding the glycosyltransferase that catalyzes the synthesis of Sd a (Sd a -B1,4GalNAcT). Introduction of this cloned cDNA into KATO III gastric or HT29 colonic cancer cell lines, which originally expressed the E-selectin ligands, sialyl Lewis 
Introduction
A blood group Sd a carbohydrate, GalNAch1-4(NeuAca2-3)Galh1-4GlcNAc, is abundantly expressed on glycolipids and glycoproteins in the normal gastrointestinal tract mucosa in the majority of humans (1) (2) (3) (4) . An important characteristic of this carbohydrate determinant is that its expression in cancer tissue is strikingly reduced or absent. In the stomach, this Sd a antigen is expressed as a glycolipid [GalNAch1-4(NeuAca2-3)Galh1-4GlcNAch1-3Galh1-4Glch1-1Cer] localized in the oxyntic mucosa but not in antral mucosa or by gastric cancer tissues (3) . In the colonic mucosa, Sd a structures are expressed on glycoproteins but not on glycolipids. The last step in biosynthesis of Sd a is catalyzed by h1,4-N-acetylgalactosaminyltransferase (h1,4GalNAcT). The Sd a determinants are synthesized by addition of N-acetylgalactosame to terminal a2,3-sialylated galactose residue in the h1,4 linkage. The activity of h1,4GalNAcT responsible for synthesizing the Sd a determinant (Sd a -h1,4GalNAcT) dramatically decreases in gastric and colonic cancer tissues from an early stage onward (5) . In the colon, the enzyme activity shows a proximal-distal gradient of expression and is attenuated in the cancer tissue itself (2, 6) . The Sd a structure is completely lost in established human gastrointestinal cancer cell lines, and this enzyme activity is not detected until the cells differentiate (7, 8) . Thus, Sd a is a differentiationassociated antigen, and the control system for its expression is significantly involved in the malignant changes in the gastrointestinal tract mucosa. However, at this point, the precise mechanisms for specific localization, differential expression on glycolipids and glycoproteins, cancer-associated alterations, and biological function of Sd a in gastrointestinal tract remain unknown.
It has long been known that malignant transformation is associated with abnormal expression of carbohydrate determinants. In these altered carbohydrate structures, the expression of sialyl Lewis x and sialyl Lewis a [NeuAca2-3Galh1-4/3(Fuca1-3/4)GlcNAc-R] by cancer tissues correlates with the progression of human carcinomas. Statistically significant correlations between the postoperative prognosis of the patients and the degree of expression of the sialyl Lewis x/a determinants in cancer tissues have been shown for both colon and stomach cancers (9) (10) (11) (12) . Further, sialyl Lewis x and sialyl Lewis a determinants in cancer cells serve as ligands for E-selectin, which is inducibly expressed by endothelial cells and functions as a cell adhesion molecule (13, 14) . Thus, interactions between E-selectin and its specific carbohydrate ligands play a significant role in hematogenous metastasis. Sialyl Lewis x determinants are synthesized by addition of fucose to GlcNAc in the a1,3 linkage with a2,3-sialylated galactose residue. The N-acetylgalactosaminylated product of the same precursor yields the Sd a antigen. Because the precursor of the sialyl Lewis a determinant as well as sialyl Lewis x are also the acceptor substrates for Sd a -h1,4GalNAcT as shown previously (15) 
Materials and Methods
Mice and reagents. Six-to 8-week-old male athymic BALB/c nude (nu/nu) mice were purchased from Japan SLC, Inc. (Hamamatsu, Shizuoka, Japan) and maintained in the animal facility under pathogen-free conditions at the International Medical Center of Japan (IMCJ; Tokyo, Japan , and anti-proton pump mAb (1H9; MBL Co., Ltd., Nagoya, Japan) were also used. All studies using human samples had been approved by the Ethics Committee of the IMCJ.
Cloning of human B1,4-N-acetylgalactosaminyltransferase. We had isolated previously the cDNA segment as a human homologue of the murine Sd a -h1,4GalNAcT (17, 18) . To obtain a cDNA containing the full-length open reading frame (ORF), the rapid amplification of cDNA ends (RACE) method was used with Human Stomach Marathon-Ready cDNA (Clontech, Palo Alto, CA). The following primers were employed: primer 1, 5V -ATCCGCCA-TCCTGTCATAC-3V and primer 2, 5V -CACCAGCACCTCAATCTTG-3V . To sequence the RACE product, the DNA fragment was purified and cloned into a pBluescript SK(+) vector (Stratagene, La Jolla, CA). Nucleotide sequences were determined with an automated DNA sequencer (Toyobo Gene Analysis, Tsuruga, Japan).
Construction and transfection of B1,4-N-acetylgalactosaminyltransferase. A 1.7-kb DNA fragment encoding the full-length ORF was obtained by PCR using the Marathon-Ready cDNA derived from human stomach as a template. For this PCR, the following primers were used: 5V -CCCCGCGGGT-GCGGAACGAACTCTGCACC-3V and 5V -GGGGATCCTATGCCCTCACACC-TTTATGCGGC-3V . The amplified fragment was digested with the restriction endonucleases SacII and BamHI followed by insertion into the pIRES2-EGFP vector (Clontech). The h1,4GalNAcT cDNA, which had been subcloned into a pIRES2-EGFP vector, was transfected into both KATO III and HT29 cells using LipofectAMINE 2000 reagent (Life Technologies, Inc., Rockville, MD). Stable transfectant cells were isolated using a FACSVantage (BD Bioscience, San Jose, CA).
Assay of B1,4-N-acetylgalactosaminyltransferase activity. The lysates of h1,4GalNAcT-transfected KATO III and HT29 cells (1 Â 10 7 ) were subjected to enzyme assay as described previously (15) using pyridylaminated oligosaccharides as acceptors (Table 1 ). In brief, the assay solution had the following final concentration in a total volume of 0.05 mL: 0.1 mol/L cacodylate buffer (pH 7.5), 0.01 mol/L MnCl 2 , 0.45% Triton X-100, 0.01 mol/L UDP-GalNAc (Sigma Chemical Co., St. Louis, MO), 0.08 mmol/L pyridylaminated oligosaccharide, and 100 Ag cell homogenate. After incubation for 2 hours, a 3 AL aliquot of the reaction mixture was analyzed with the highpressure liquid chromatography system equipped with a fluorescence monitor Shimadzu RF-535T.
Flow cytometry. Flow cytometry was done with a FACScan (BD Bioscience, Palo Alto, CA). Cells were stained with the mouse mAbs as above, biotin-conjugated horse anti-mouse immunoglobulin (Vector Laboratories, Inc., Burlingame, CA) and then phycoerythrin (PE)-conjugated streptavidin (BD PharMingen, San Diego, CA).
Quantification of B1,4-N-acetylgalactosaminyltransferase mRNA by reverse transcription-PCR. The conditions for reverse transcription-PCR (RT-PCR) and primers used for h1,4GalNAcT are described previously (18) . Expression of h1,4GalNAcT mRNA was quantified by PCR using SYBR Green PCR Master Mix (Applied Biosystems, Foster City, CA) and Sequence Detector (ABI 7700 version 1.7, Applied Biosystems) using glyceraldehyde-3-phosphate dehydrogenase as the calibrator gene.
Western blotting and immunostaining of TLC. SDS-PAGE for cell lysates (2 Â 10 5 cells per lane) was done using 3% to 10% gradient gels under reducing conditions. After electroblotting, the membrane was stained with the indicated mAbs, followed by horseradish peroxidase-conjugated goat anti-mouse IgM antibodies (Southern Biotechnology Associates, Inc., Birmingham, AL). For TLC, lipids extracts from cells were fractionated by Folch's partition, purified with Sep-Pak C18 column (Waters Corp., Milford, MA), and spotted on TLC plates. TLC was done with high-performance TLC plates (Whatman, Inc., Clifton, NJ) using a solvent system of chloroform/ methanol/water containing 0.05% CaCl 2 (50:40:10 by volume) and immunostained with the indicated mAbs as described previously (3) .
Cell adhesion assays. To evaluate the E-selectin-dependent adhesion of the human gastrointestinal cancer cell lines, tumor necrosis factor-a (TNF-a)-activated HUVEC were used as previously described (19) . Briefly, HUVEC were plated at a density of 2 Â 10 5 cells per well in 24-well multiwell plates 24 hours before assay. These cells were stimulated with 200 units/mL recombinant human TNF-a (PeproTech, London, United Kingdom) for 3 hours before assay. Transfectants were labeled with 3V -O-acetyl-2V ,7V -bis(carboxyethyl)-4 or 5-carboxyfluorescein diacetoxymethyl ester, and cells (2 Â 10 5 ) were placed in 24-well tissue culture plates containing HUVEC and incubated for 30 minutes at 4jC. After washing, the attached cells were lysed in 1% Triton X-100 at 37jC. The fluorescence intensity of the lysates was assessed with a fluorescence spectrophotometer (Hitachi U-3000, Hitachi Ltd., Tokyo, Japan). 
Binding assays to Siglec immunoglobulin chimera. Binding studies using recombinant Siglec-3, -5, -7, or -9 immunoglobulin chimera (R&D Systems, Inc., Minneapolis, MN) were done as described previously (20) . In brief, recombinant Siglec immunoglobulin chimera was preincubated with affinity-purified rabbit anti-human IgG (DAKO, Glostrup, Denmark) followed by incubation with PE-conjugated streptavidin before application to the binding analyses with transfectants. Binding of recombinant molecules to the cells was evaluated by flow cytometry. For the inhibition experiments, the cells were incubated with blocking antibodies (10 Ag/mL) for 30 minutes at 37jC.
In vivo metastasis assay. Exponentially growing KATO III cells were harvested and suspended in HBSS. Suspensions of KATO III cells (1 Â 10 7 ) were injected into the peritoneal cavity of individual male athymic mice. The mice were sacrificed 10 weeks later, and tumor lesions were examined. Twelve or 13 mice per group were used in this model. In some experiments, HT29 cells (1 Â 10 6 ) were injected intrasplenically, and nodule formation in the liver was numerated 8 weeks later. Three to five mice per group were used in this hepatic metastasis model.
Immunohistochemical analysis. This study was approved by the Ethics Committee of the IMCJ, and informed consent was obtained for the taking of all samples. Frozen sections (8 Am thick) were prepared from a surgical specimen. After fixation in acetone and blocking with 3% bovine serum albumin (BSA) in PBS, sections were incubated with the indicated primary mAbs (5 Ag/mL) for 2 hours. Bound mAbs were detected with FITCconjugated goat anti-mouse IgM (1:800 dilution) or TRITC-conjugated goat anti-mouse IgG (1:800, Southern Biotechnology Associates).
Cell separation from gastric mucosa. Separation procedures followed a previously reported method (21) with some modifications. In brief, surgically obtained human gastric mucosa was washed, minced, and then incubated in HBSS with 0.1% BSA, 1 mmol/L EDTA, 3 mg/mL Dispase (Roche Diagnostics Corp., Indianapolis, IN), and 0.15 mg/mL collagenase (Sigma Chemical) for 20 minutes. The residue was further digested with Dispase and collagenase two more times, and the cell suspension was passed through a nylon mesh. Next, the cells were suspended in 40% Percoll and centrifuged with a vertical rotor at 30,000 Â g for 15 minutes, which allowed separation of three cell fractions.
Assay for pepsinogen activity. Cells or various concentrations of standard porcine pepsinogen were incubated with 0.1 N HCl containing 1.8% hemoglobin and 6 mmol/L glycine for 15 minutes at 37jC. After stopping this reaction with 0.9% trichloroacetic acid, the solution was centrifuged and the supernatant was assessed at A 280 nm .
Statistics. The data were expressed as the mean F 1 SD, and the results were compared by the two-tailed, unpaired Mann-Whitney, Student's t test or m 2 test using the Statview II statistical program (Abacus Concepts, Berkeley, CA).
Results
Expression of Sd a determinant in the normal human stomach and in gastric cancer. We found previously that Sd a carbohydrate determinant was expressed in the oxyntic mucosa of the human normal stomach. With the final aim of understanding the function of the Sd a antigen, we initiated studies to determine the cell types that express Sd a in the gastric body mucosa. In an immunohistologic study, cells at the base of the gastric glands were exclusively expressing the Sd a determinant (Fig. 1A) . The Sd a was detected only in normal stomach but was not in gastric cancer tissue, confirming our earlier results (Fig. 1B) . Most of the cells expressing Sd a were positively stained with anti-pepsinogen mAb, which was used as a chief cell marker, but were not stained with anti-proton pump mAb, a parietal cell marker (Fig. 1C and D) . To further confirm that Sd a glycolipid is expressed in chief cells, we did cell separation from human stomach mucosa. Cells obtained from the gastric mucosa were divided into three fractions by centrifugation over 40% Percoll. Fraction 1 was rich in parietal cells having the typical morphology (Fig. 1E, top) . Chief cells were enriched in the middle fraction ( fraction 2; Fig. 1E, middle) . Mucous cells were concentrated in fraction 3 (Fig. 1E, bottom) . Pepsinogen activity was concentrated in fraction 2 (Fig. 1F) . The Sd a glycolipid was detected in chief cell-enriched fraction, whereas neither fraction 1 nor fraction 3 expressed Sd a glycolipids (Fig. 1G ). The cells in the chief cell-enriched fraction also contained higher levels of h1,4GalNAcT activity than those in the parietal cell-rich or the mucous cell-enriched fractions (Fig. 1H) . These results indicate that chief cells are the major source of the Sd a glycolipid, which is formed by h1,4GalNAcT.
Cloning and characteristics of the human Sd a -B1,4GalNAcT cDNA. In our next series of studies, we cloned a cDNA containing the full-length ORF of human h1,4GalNAcT by the RACE method using a cDNA segment, which we had isolated previously as a human homologue of the murine Sd a -h1,4GalNAcT (18) . The human h1,4GalNAcT nucleotide sequence showed a 1,701-bp ORF encoding a predicted 566-amino acid protein with a typical type II topology, which is common in glycosyltransferases. It shares a 78.8% nucleotide identity with the murine Sd a -h1,4GalNAcT (17 Fig. 2A and B) . These results show that the cDNA clone encodes a h1,4GalNAcT identical to human Sd a -h1,4GalNAcT expressed in the human stomach. There was no alteration in cell growth or viability after Sd a -h1,4GalNAcT transfection. Elimination of selectin ligands by introduction of the human Sd a -B1,4GalNAcT. Sd a -h1,4GalNAcT and fucosyltransferases, which produce sialyl Lewis x and sialyl Lewis a , share acceptor carbohydrates. As expected, transfection of KATO III cells with Sd a -h1,4GalNAcT caused loss of expression of sialyl Lewis x ( Fig. 2A) . These results were confirmed by TLC immunostaining and Western blot analysis. In mock-transfected KATO III cells, the Sd a was present in only trace amounts in the glycolipid extracts (Fig. 3A) , although GM2 ganglioside was visible because of its weak cross-reactivity. In contrast, KATO III cells transfected with Sd a -h1,4GalNAcT expressed Sd a glycolipids, with concomitant elimination of sialyl Lewis x (Fig. 3A) . As expected from the substrate specificity where Sd a -h1,4GalNAcT uses both glycolipids and oligosaccharide as acceptor substrates, these changes were also evident in glycoproteins (Fig. 3C) Fig. 2A) . Introduction of the Sd a -b1,4GalNAcT gene into HT29 cells resulted in the loss of expression of sialyl Lewis a in glycolipids and glycoproteins ( Fig. 3B and D) . Sialyl Lewis x was not expressed on glycolipids in the original HT29 cells. Furthermore, we obtained several clones of stably Sd ah1,4GalNAcT-transfected KATO III cells (Fig. 2C ) and HT29 cells (Fig. 2D) , which expressed Sd a -h1,4GalNAcT mRNA at different levels: high, intermediate, and low. These clones also expressed different levels of cell surface Sd a , which paralleled the mRNA produced ( Fig. 2C and D (Fig. 4A and B) . The same results were obtained with HT29 Sd a -h1,4GalNAcT transfectants (Fig. 4C ). The contribution of E-selectin was established by the blocking effect of anti-E-selectin mAb (Fig. 4C) . These results clearly show that the introduction of Sd a -h1,4GalNAcT abolished Eselectin-dependent adhesion of cancer cells to endothelial cells in vitro.
Sd a does not bind to Siglec family molecules. Siglec family molecules are sialic acid-dependent cell adhesion molecules. Siglec-7 has been reported to have a binding activity to a certain carbohydrate (disialyl Lewis a ), which is expressed preferentially on nonmalignant colonic epithelial cells (20) . Assuming that Sd a may be ligand for the Siglec family, we next tested the binding of Sd a -h1,4GalNAcT transfectants to recombinant Siglec-3, -5, -7, and -9 immunoglobulin chimera. However, direct binding of Sd a determinant to Siglec proteins was not detected (data not shown).
Inhibition of tumor metastasis by introduction of Sd a -B1,4GalNAcT. We next evaluated the effects of directed expression of Sd a -h1,4GalNAcT in gastrointestinal cancer cells on their metastatic potential. Mock-transfected KATO III cells metastasized to the spleen, liver, peritoneum, and seminal vesicles when injected into the peritoneal cavity of nude mice ( Fig. 5 ; Table 2 ). In contrast, mice inoculated with Sd a -h1,4GalNAcT-transfected KATO III cells developed no macroscopic tumor lesions (Table 2) . Although several sections of the spleen, liver, and seminal vesicles were prepared and examined histologically, there were no metastatic foci in mice given Sd a -h1,4GalNAcT-transfected KATO III cells. The colorectal cancer cell line HT29 was also used to test hematogenic metastasis in the liver. Eight weeks after intrasplenic injection, tumor nodules were established in the primary site of all mice injected with both mock-transfected and Sd a -h1,4GalNAcT-transfected HT29 cells, indicating that there was no difference in cell growth or viability in vivo between them. Metastatic nodules were seen in the liver of all mice injected with mock-transfected HT29 cells; however, Sd a -h1,4GalNAcT-transfected metastatic foci occurred in only one of the mice tested (Table 2) . These results clearly show that the introduction of Sd ah1,4GalNAcT efficiently inhibited tumor metastasis of sialyl Lewis x/a -positive cancer cells.
Discussion
There are significant correlations between the degree of expression of sialyl Lewis x/a determinants in cancer tissues and the postoperative prognosis of patients with colon, lung, breast, stomach, prostate, and urinary bladder cancers (10) (11) (12) (23) (24) (25) (26) . Therefore, elimination of the sialyl Lewis x/a determinants from cancer cells has been an important goal for the control of cancer metastasis. The present study provides direct evidence that the production of this Sd a determinant by the action of a specific glycosyltransferase, Sd a -h1,4GalNAcT, efficiently eliminated sialyl Lewis x/a from cancer cells, reduced the E-selectin-mediated adhesion of these cells to the endothelium, and efficiently abolished metastasis in vivo. Through this analysis, we found that introduction of the Sd a -b1,4GalNAcT gene essentially inhibited the expression of sialyl Lewis x and sialyl Lewis a from both glycoprotein and glycolipid components. Further, these effects were essentially independent of the number of copies of the Sd a -b1,4GalNAcT gene expressed. It is of note that the presence of this single glycosyltransferase led to profound changes in the types of carbohydrate determinants displayed by the cancer cells.
Many glycosyltransferases participate in the total biosynthesis of sialyl Lewis x and sialyl Lewis a , and their synthesis is completed by the final addition of sialic acid and fucose by the action of a2,3 sialyltransferases and a1,3/4 fucosyltransferases (Fig. 6 ). To our knowledge, even for this final step, seven genes encoding the a2,3 sialyltransferase family and six human a1,3/4 fucosyltransferase genes are likely involved (27) . Extensive studies on the expression levels of these sialyltransferases and fucosyltransferases in gastrointestinal tract cancers have been carried out; however, the precise mechanisms for up-regulation of sialyl Lewis x/a has not yet been determined (28) (29) (30) . Apparently, the final expression levels of sialyl Lewis x/a epitopes in colon cancer tissues are not controlled by a single glycosyltransferase but through a combinatorial effect of multiple glycosyltransferases. Based on this fact, the interruption of a certain fucosyltransferase [e.g., FUT3 (31)] may not always result in the elimination of sialyl Lewis x/a in human cancers, because other fucosyltransferases, such as FUT4-FUT7, may be also involved in the up-regulation of sialyl Lewis x/a in cancer tissues. In the present study, we showed that introduction of a single glycosyltransferase, Sd a -h1,4GalNAcT, resulted in the total loss of both sialyl Lewis x and sialyl Lewis a epitopes from both glycolipids and glycoproteins. Because Sd ah1,4GalNAcT uses substrates that are required in the very last step in the synthesis of sialyl Lewis x/a as shown in Fig. 6 , this effect should be seen in any cancer cells that express high levels of sialyl Lewis x/a irrespective of the underlying mechanism for expression. Thus, it is a great advantage that introducing a single gene for one enzyme is able to alter the expression of functional carbohydrates dramatically, whose expression is actually under multifactorial control. It is also notable that the elimination of sialyl Lewis x/a occurred irrespective of the expression levels of the Sd a -h1,4GalNAcT, which suggests that Sd a -h1,4GalNAcT has a strong potential to compete for substrates with other glycosyltransferases at the site of glycosylation of proteins and glycolipid synthesis. If Sd a -h1,4GalNAcT is a dominant enzyme in the terminal modification of carbohydrates as our data clearly suggest, the loss of its activity in gastrointestinal tract cancers may contribute to the up-regulation of sialyl Lewis x/a as a part of the malignant transformation progress. The nature of the mechanisms regulating the tissue-specific expression and cancer-associated down-regulation of Sd a -h1,4GalNAcT remains a major question to be answered. Clearly, this approach is important because it will provide the tools necessary to manipulate the expression of Sd a by modifying the regulation system at the translational level. Defining the details of this mechanism for expression of the Sd a antigen in relation to that of sialyl Lewis x/a is also a challenge for future studies of the regulation of glycosylation by glycosyltransferase activities.
Another important feature of Sd a -h1,4GalNAcT is its relatively broad substrate specificity. It is known to catalyze reactions that add GalNAc in h1,4 linkage to both glycolipids and glycoproteins with both type 1 and 2 core chains as acceptor oligosaccharide substrates (Fig. 6 ). This characteristic substrate usage resulted in total elimination of sialyl Lewis x/a from both glycolipids and glycoproteins. Previously, two research groups introduced FUT1, which catalyzes the addition of a terminal fucose in a1,2 linkage to a lactosamine residue, into HT29 cancer cells and succeeded in reducing the level of sialyl Lewis x (32, 33) . However, their results with sialyl Lewis a were inconsistent. The discrepancy between these two studies seems to be derived from the heterogeneity of expression patterns of carbohydrates that can occur in a cancer cell line (33) . This again indicates the difficulty in applying gene delivery of FUT1 for the treatment of cancer cells in the human gastrointestinal tract, which displays immense heterogeneity and variation. In addition, FUT1 activity is already up-regulated in human colon cancer (34) . In contrast, our approach using Sd a -h1,4GalNAcT could be more beneficial than that used in the above trials to ensure reduction of both sialyl Lewis x and sialyl Lewis a , when safe and sufficient methods to transduce genes for clinical application are developed. In addition, Sd a -h1,4GalNAcT would be applicable for not only gastrointestinal tract cancer but also cancer of the pancreas and biliary tracts, where the expression of sialyl Lewis a is significantly correlated with the postoperative prognosis of patients with these cancers (34, 35) .
Because the regulation system for Sd a expression and its function is still unknown, it is difficult to predict any possible adverse effects of the forced expression of Sd a in vivo. In this study, we attempted to assume a function for the Sd a antigen by determining its cellular localization in the stomach. We found that Sd a glycolipid was expressed in chief cells. It explained in part that both Sd a antigen and Sd a -h1,4GalNAcT activity were strikingly reduced or absent in the antral mucosa, intestinal metaplasia, and gastric cancer tissue because of the absence of chief cells in these tissues. However, the relation of Sd a with the function of chief cells remains to be elucidated. The Sd a carbohydrate showed no apparent binding to the Siglec family molecules, adhesion molecules that recognize sialic acid residues. The Sd a glycolipids were not detected in gastrointestinal tract cancers, and in vitro Sd a expression was associated with growth inhibition caused by induction of differentiation by dimethylformamide (7). We did not see changes in cell growth or viability after Sd a -h1,4GalNAcT transfection in this study. These results at least tell us that Sd a is not expressed where malignant changes occurs in the gastrointestinal tract.
Our results clearly show that the normalization of surface carbohydrates by directed expression of a single glycosyltransferase, Sd a -h1,4GalNAcT, efficiently decreased the metastatic potential of sialyl Lewis x/a -positive cancer cells. We feel that manipulation of gastrointestinal cancer cells to make them express Sd a is a promising approach for controlling metastasis. Certainly, we need to gain further knowledge about the regulation of their expression system and their biological functions.
